Meeting
2021 ASCO Annual Meeting
Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Presenter
Van K. Morris, MD
The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT04068103
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3622)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3622
Abstract #
TPS3622
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
Speaker: Van K. Morris, MD
Videos & Slides
2021 Gastrointestinal Cancers Symposium
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Speaker: Van K. Morris, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Speaker: Van K. Morris, MD
Speaker: Panel Discussion